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The obesity epidemic has drastically impacted the state of health care in the United States. 
Paralleling this epidemic is the incidence of diabetes mellitus, with a notable shift toward 
a much younger age of onset. While central to the pathogenesis of diabetes associated 
with obesity is the role of inflammation attributed to “adiposopathy.” Emerging data 
suggest that changes in sympathetic/parasympathetic balance regulated by the brain 
precede changes in the inflammatory cascade. It has now been established that the gut 
microflora contributes significantly to the activation and inhibition of autonomic control 
and impact the set of the neuroinflammatory inhibitory reflex mediated by the cholinergic 
nervous system. There has been a paradigm shift toward further investigating commen-
sal bacteria in the pathogenesis of obesity and diabetes mellitus and its complications, 
as dysbiosis is thought to play a pivotal role in diabetic-associated disorders. This paper 
is intended to evaluate the role of intestinal dysbiosis in the pathogenesis of diabetes 
mellitus and examine the potential for restoration of balance via use of probiotics.
Keywords: diabetes, intestinal microbiome, autonomic nervous system, intestinal dysbiosis, metabolic syndrome, 
obesity
iNTRODUCTiON
The incidence of diabetes mellitus continues to rise at historic rates, paralleling that of the obesity 
epidemic (1). Superimposed on this worldwide epidemic, clinicians are seeing a demographic trend 
to an even younger age of diagnosis of diabetes mellitus type 2 (T2DM) (2). Currently, therapeutic 
approaches mainly target the sequelae of disease, whereas research efforts are directed toward 
addressing the underlying cause of impaired metabolism (3, 4). There has been considerable inter-
est in the role of autonomic balance (5, 6) and the intestinal microbiota may play in this disease, 
with emerging data implicating a brain–gut dysbiosis in the pathogenesis of obesity, diabetes, and 
metabolic syndrome (7). In this review, we examine the most current literature focusing on the 
emerging links between the gut microbiome brain axis and its role in the pathogenesis of diabetes 
mellitus and its complications.
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“MeTABOLiC iNFeCTiON” – MiCROBiOTA 
AND A LOw-GRADe iNFLAMMATORY 
STATe
The metabolic alterations associated with obesity also cause 
a chronic low-grade inflammatory state, which affects energy 
homeostasis and glucose metabolism (7). Diabetes mellitus has 
long been thought of as low-grade inflammatory state, secondary 
to adipocyte necrosis (8–10). The imbalance between caloric 
intake and energy expenditure results in adipocyte hypertrophy, 
culminating in local hypoxia and apoptosis (10). As a result, these 
adipocytes begin to secrete TNF-α in low quantities, thereby 
stimulating a chemotactic response (7, 10).
Cani et al. suggested that bacterial lipopolysaccharide (LPS) 
was responsible for this low-grade inflammatory state (11). They 
demonstrated that levels of endotoxemia fluctuated depending 
on whether or not the host was in a fasting or fed state. After 
a 4-week high-fat diet was introduced, levels of LPS-producing 
microbiota had significantly increased. In addition, continuous 
subcutaneous infusion of LPS resulted in fasting hyperglycemia 
and hyperinsulinemia, associated with whole-body, liver, and 
adipose tissue weight gain that was comparable to those mice fed 
a high-fat diet for 4 weeks. As the hepatic, but not whole-body, 
insulin resistance was seen in LPS-infused mice, the authors 
concluded that metabolic endotoxemia results in a low-grade 
inflammatory state and acts as a trigger for insulin resistance 
and the onset of diabetes and obesity. The findings by Cani et al. 
indicate that LPS is in fact a trigger for the early development 
of metabolic disease and is involved early in the inflammatory 
cascade as it stimulates a number of key cytokines (evidenced by 
increased expression of genes encoding IL-6, TNF-α, IL-1, and 
PAI-1 in adipose, liver, and muscle). This upregulation is pivotal 
in the development of insulin resistance via its effect on mCD14 
and toll-like receptor (TLR)-4.
Remely et al. evaluated the impact of intestinal dysbiosis on 
the upregulation of pro-inflammatory cytokines, namely, TLRs 2 
and 4 in three groups of subjects: subjects with T2DM receiving 
glucagon-like peptide-1 (GLP-1) agonist therapy, obese subjects 
without established insulin resistance, and a lean normative 
control group (12). They found there to be a significantly higher 
ratio of Firmicutes:Bacteroides in the diabetes cohort compared to 
their lean and obese counterparts. In addition, Faecalibacterium 
prausnitzii were least abundant in the diabetes cohort and most 
prevalent in lean controls. Methylation analysis demonstrated 
significantly lower methylation of TLRs 2 and 4 in the diabetic 
group compared to obese and lean controls, with levels signifi-
cantly correlating with body mass index. The authors suggested 
that the changes in commensal microbiota-induced changes and 
subsequent alterations in cell components are involved in the 
epigenetic regulation of the inflammatory cascade. Endotoxin 
LPS is invariably associated with Gram-negative bacteria whether 
the organisms pathogenic or not. While normally LPS endotox-
emia triggers the inflammatory process by binding to the TLR-4 
complex at the surface of innate immune cells triggering the host 
inflammatory cascade, ultimately resulting in insulin resistance; 
counterintuitively, it was lower levels of Gram-negative Bacteroides 
that was associated with diabetes. One possible explanation is the 
impaired innate immune system. The commensal relationship 
between host and the gut microbiome is pivotal in maintaining 
the integrity of the immune system. Bacteroides has been dem-
onstrated to influence the activity of defensins (e.g., angiogenin), 
which regulated the microbial system and innate immunity when 
secreted; thus, a populous deficient would be predisposed to 
intestinal dysbiosis and inflammation (13).
Apelin is hormone produced by adipose tissue that is thought 
to play a key role in the regulation of homeostasis and low-grade 
inflammation (14, 15). Geurts et  al. investigated the microbial 
composition in obese and diabetic leptin-resistant mice (db/db) 
in order to establish the role of specific microbial strains and their 
gut-derived compounds, i.e., LPS, in adipose tissue metabolism 
via the endocannabinoid system (14). They found db/db mice to 
have a significantly higher populous of Firmicutes, Proteobacteria, 
and Fibrobacteres phyla compared to the lean cohort. In addition, 
they were able to demonstrate the roles of the endocannabinoid 
system and LPS in regulating apelinergic tone. Using in vitro and 
in vivo models, they found both the endocannabinoid system and 
low-grade inflammation to regulate apelin expression in adipose 
tissue. Lastly, microbiota profiling revealed the commensal 
microbiota of T2DM mice to significantly differ from that of their 
lean counterparts, indicating a specific relationship between the 
microbiome and regulation of the apelinergic system.
The next step was to demonstrate the role of intestinal dysbio-
sis in the occurrence of diabetes mellitus. Cani et al. administered 
antibiotics in order to alter commensal microbiota to evaluate 
whether intestinal dysbiosis is responsible for metabolic endo-
toxemia, low-grade inflammation, obesity, and diabetes and also 
to determine what underlying mechanisms are at play (16). They 
found that antibiotic-induced microbial changes had reduced 
metabolic endotoxemia and cecal content of LPS compared to 
high-fat fed mice and genetically obese mice (ob/ob). This cor-
related with reduced glucose tolerance, inflammation, oxidative 
stress, body weight gain, development of fat mass, and macrophage 
infiltration marker mRNA expression in visceral adipose tissue. 
Mice subjected to high-fat feeding strongly increased intestinal 
permeability and reduced expression of proteins responsible for 
tight junctions. Lastly, genetically altered mice that lack func-
tional LPS receptors (CD14 knockout mice) exhibited similar 
characteristics as mice subjected to antibiotics (i.e., resistant to 
diet-induced obesity and hepatic insulin resistance). Subsequent 
metagenome-wide studies have demonstrated the presence of 
intestinal dysbiosis in patients with T2DM (17, 18), of interest a 
decrease in the abundance of some universal butyrate-producing 
bacteria (17), which can alter energy homeostasis, further sup-
porting the concept of intestinal dysbiosis and metabolic endo-
toxemia and its sequelae set forth by Cani et al. (16).
More recent studies have aimed to investigate the impact of 
diet on alteration of commensal microbiota and potentially iden-
tify specific bacterial strains that predominate diabetes-induced 
low-grade inflammation. Fallucca et  al. investigated the use of 
the macrobiotic Ma-Pi 2 diet in patients with T2DM for 21 days 
(19). The Ma-Pi2 diet is one that is low in fat, protein, and fructose 
containing no animal protein or sugar. It is rich in complex carbo-
hydrates, natural fibers, and most significantly prebiotic and pro-
biotic products (20). The investigators found there to be significant 
FiGURe 1 | The relationship between binding of ligands to the pattern recognition AGe receptor (RAGe) and inflammation, gene expression, 
oxidative and nitrosative stress, and activation of an inflammatory cascade involving a cadre of inflammatory cytokines as an afferent arc impacting 
the brainstem nuclei initiating an efferent arc, in which acetylcholine binds to its receptor inhibiting the activation of the inflammatory cascade.
3
Parekh et al. Gut Microflora and the Cholinergic Anti-inflammatory Neuroendocrine System in Diabetes Mellitus
Frontiers in Endocrinology | www.frontiersin.org June 2016 | Volume 7 | Article 55
reduction of fasting blood glucose, plasma lipid  fractions, plasma 
insulin, and energy homeostasis by implementing the Ma-Pi 2 
diet supporting the role of intestinal dysbiosis in the development 
of diabetes mellitus and that manipulation of the gut microbiome 
may be a promising therapeutic option. Subsequent studies have 
also demonstrated the Ma-Pi 2 diet to reduce markers of insulin 
resistance, inflammation, and insulin growth factor-1, support-
ing its use in patients with T2DM (21–23). None of these studies 
aimed to understand the link between the intestinal dysbiosis and 
the metabolic derangements found.
ROLe OF SPeCiFiC BACTeRiAL STRAiNS
Several studies have suggested the protective benefit of 
Lactobacillus casei against diabetes mellitus (24–29). A recent 
study by Chen et al. evaluated the antidiabetic effects of L. casei 
on mice using a model of T2DM induced by a high-fat diet and 
low-dose streptozotocin (24). Administration of L. casei signifi-
cantly reduced fasting and postprandial 2-h serum glucose levels, 
hemoglobin A1c levels, other markers of metabolic syndrome 
[e.g., triglycerides, total cholesterol, and low-density lipoprotein 
cholesterol (LDL-C)], and markers of inflammation (e.g., TNF-α, 
endotoxin) compared to control. In addition, islets of Langerhans 
were substantially protected against destruction when exposed 
to L. casei compared to controls, which led to the conclusion that 
oral administration of L. casei may have a role in the primary 
prevention of diabetes mellitus. A subsequent study by Zhang 
et al. postulated that L. casei might induce its antidiabetic effects 
by acting on the bile acid-chloride transport (25), while we will 
suggest an alternative mechanism as detailed in the enhancement 
of the neuroinflammatory reflex (see Figure 1).
Unequivocal evidence demonstrates the impact of the gut 
microbiota on whole-body metabolism and energy homeostasis 
(7); however, the microbial composition and the underlying 
mechanisms of interaction between host and commensal micro-
biota that impact host–gut barrier function and metabolism 
remain unclear. Recent efforts have shifted focus onto the poten-
tial role Akkermansia muciniphila (30–37) and F. prausnitzii (12, 
38–42) in mediating diet-induced obesity and T2DM. A study by 
Everard et al. isolated A. muciniphilia (a mucin-degrading Gram-
negative bacterium) within the mucous layer (30). Studies have 
demonstrated there to be a relative decrease in the population of 
A. muciniphilia in obese mice and mice with T2DM compared to 
lean cohorts (30). In addition, the use of prebiotics to reconstitute 
the population of A. muciniphilia resulted in improved metabolic 
profiles, reversal of high-fat diet-induced metabolic disorders 
(e.g., obesity, metabolic endotoxemia, adipocyte hypertrophy, 
and insulin resistance), increased intestinal levels of endocan-
nabinoids that regulate inflammation, gut mucosal integrity, and 
intestinal peptide secretion, which ultimately results in restora-
tion of the intestinal barrier (29). At present, the role of A. mucin-
iphilia in the pathogenesis of obesity and T2DM are not known; 
however, studies suggest that the proximity of A. muciniphilia to 
the intestinal epithelium allows it to control gut barrier function, 
fat mass storage, and regulate glucose homeostasis (30).
Faecalibacterium prausnitzii is considered the prototypical 
anti-inflammatory bacterium and, thus, is among the most 
studied in a variety of disease states characterized and driven by 
4Parekh et al. Gut Microflora and the Cholinergic Anti-inflammatory Neuroendocrine System in Diabetes Mellitus
Frontiers in Endocrinology | www.frontiersin.org June 2016 | Volume 7 | Article 55
inflammation (43, 44). Remely et al. recently studied the potential 
interaction between commensal microbiota in obese patients and 
patients with T2DM (38). These patients were compared to a lean 
cohort and evaluated over a 4-month intervention period (inter-
ventions comprised a GLP-1 agonist for those with T2DM and 
nutritional counseling for both groups). Through high-throughput 
sequencing and pyrosequencing, they found microbial diversity 
and the populous of F. prausnitzii to be significantly decreased in 
obese patients and patients with T2DM when compared to their 
lean counterparts. In addition, analysis of CpGs in the promoter 
region of FFAR3 demonstrated markedly lower methylation in 
obese patients and patients with T2DM, which increased in obese 
patients over the intervention period, thus showing a significant 
correlation between a higher body mass index and lower meth-
ylation of FFAR3. These results suggest that differing microbial 
makeups affect epigenetic regulation of FFAR-3 and possibly 
LINE-1 in obese patients and patients with T2DM.
TARGeTeD THeRAPY: DieT, PROBiOTiCS, 
PReBiOTiCS, AND FeCAL TRANSPLANT
The composition and behavior of gut microbiota can be largely 
influenced via diet (45); therefore, the next logical question would 
be to see if diet has any contribution to the development or pro-
gression of diabetes. Since diabetes is known to be a multifactorial 
disorder, adjunctive therapeutic approaches beyond focused 
glycemic control may be helpful (46). Much of the research into 
this topic been focused on the use of prebiotics, probiotics, and 
fecal transplant.
Prebiotics
Prebiotics are defined as non-digestible, fermentable carbohy-
drates (45, 47) that have the ability to influence the gut microbiota 
in order to provide a health benefit to the host (48); some examples 
of such prebiotics are inulin, oligofructose, and resistant starch 
(47). There are many natural foods that contain prebiotics in 
their raw form, such as chicory root, Jerusalem artichoke, barley, 
garlic, onion, globe artichoke, rye bran or grain, wheat bran, and 
asparagus; chocolate and white bread are examples of cooked or 
processed foods that contain prebiotics (45). A recent review of 
several randomized control trials of the effect of prebiotics on 
patients with prediabetes and T2DM by Barengolts et al. found 
that dietary changes (which include prebiotic supplementation) 
may ameliorate the effects of impaired insulin signaling and 
secretion (45).
In obese humans and genetically obese mice, a decrease 
in Bacteroidetes and an increase in Firmicutes phyla have been 
observed when compared to lean humans/mice (31, 45, 49, 50). 
Using genetically obese and diabetic mice, Everard et al. reported 
that a prebiotic-enriched diet resulted in changes of 102 distinct 
taxa, 16 of which displayed a >10-fold change in abundance. Of 
these results, two of particular importance was an increase in 
Bacteroidetes and a decrease in Firmicutes phyla; the obese mice 
fed a prebiotic-enriched diet showed a shift in two dominant phyla 
toward a profile more similar to lean mice (51). Prebiotics were 
also shown to improve many metabolic parameters, including 
lower fasting glycemic levels, improved glucose tolerance (52), 
reduced plasma triglyceride levels (47, 51), muscle lipid infiltra-
tion, adipose tissue mass, and oxidative stress, and increased 
leptin sensitivity (51).
Outside of affecting the composition of bacterial phyla, these 
fermentable carbohydrates play a role in the pathogenesis of T2DM 
and low-grade inflammation. One example is Bifidobacteria, 
whose growth can be nurtured via the supplementation of 
prebiotics, specifically dietary fructans. Bifidobacteria express 
the enzyme β-fructofuranosidase that allows them to break down 
fructans for energy (53). This is important because the number 
of Bifidobacteria is decreased in patients with diabetes mellitus, 
when compared to non-diabetics (53). In mice fed a high-fat diet 
supplemented with the prebiotic oligofructose, Bifidobacterium 
was shown to significantly and positively correlate with improved 
glucose tolerance, insulin secretion, and decreased inflammatory 
markers (54).
Prebiotics have also been shown to modulate the enteroen-
docrine and neuroendocrine brain systems via gastrointestinal 
peptides and neural signaling. Studies have shown that prebiotic 
supplementation can increase plasma glucagon-like peptide 1 
(GLP-1) and plasma glucagon-like peptide 2 (GLP-2) (52, 54–56). 
In the setting of gut microbiota and diabetes, GLP-1 is thought 
to play a role in reducing appetite, fat mass, and hepatic insulin 
resistance (52), while GLP-2 is believed to reduce metabolic endo-
toxemia by decreasing intestinal wall permeability (57). Prebiotic 
treatment has also been shown decrease satiety and postprandial 
plasma glucose response after a standardized meal (54). It is pos-
sible that one of the mechanisms in which prebiotics contribute to 
changes in satiety and postprandial glucose excursion responses 
is through the modifications of these gastrointestinal peptides.
Probiotics
Probiotics are living microorganisms that can improve the health 
of its host by altering the intestinal microflora when ingested (58). 
Research using in vivo and in vitro animal models has shown that 
probiotics may have a beneficial role in preventing and treating 
diabetes (46). L. casei is one example that has been proven to have 
anti-hyperglycemic capabilities in a diabetic mouse model. One 
group of researchers showed that supplementation of heat-killed 
L. casei cells exhibited decreased plasma glucose levels in a type 
1 diabetic mouse model and prevented the onset of diabetes in a 
type 2 diabetic mouse model (26, 28). Another example included 
feeding Lactobacillus rhamnosus subtype GG to diabetic rats, 
which in 9 weeks had lowered the blood hemoglobin A1c level 
and improved glucose tolerance when compared to rats fed with 
normal diet (59). Along with improving diabetic parameters, 
probiotic supplementation in animals has also shown to decrease 
beta cell destruction, reduce oxidative damage to the pancreas, 
exhibit anti-inflammatory properties by increasing liver natural 
killer cells, reduce bacterial translocation from the intestine into 
the host, and decrease expression of pro-inflammatory cytokines 
(27, 60–62).
Unfortunately, there are few studies using probiotic therapy in 
diabetic human populations. Of the research available, it has been 
shown that probiotic supplementation can significantly reduce 
both the oxidative stress and associated inflammatory response, 
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along with decreasing intestinal permeability (63). These  favorable 
effects are thought to lead to greater insulin sensitivity, a decrease 
in autoimmune response (63), and an improvement in autonomic 
balance (see Figure 1).
A study in 2012 found that probiotic yogurt (already containing 
Lactobacillus bulgaricus and Streptococcus thermophiles) enriched 
with Lactobacillus acidophilus (La5) and Bifidobacterium lactis 
(Bb12) significantly decreased fasting blood glucose and hemo-
globin A1c (58). Additionally, there was associated improved 
antioxidant status (increased erythrocyte superoxide dismutase, 
glutathione peroxidase activity) in patients with T2DM when 
compared to patients supplemented with regular, unenriched 
yogurt (containing only L. bulgaricus and S. thermophiles). The 
authors concluded that the decrease in oxidative stress likely 
resulted from anti-inflammatory and immunomodulatory prop-
erties of enriched probiotics. In that, oxidative/nitrosative stress 
plays a role in the initiation and progression of diabetes (64) and 
autonomic neuropathy (65); the addition of probiotics may be a 
potential adjunctive therapy in diabetics or perhaps a primary 
approach in pre-diabetics and in particular those with newly 
diagnosed neuropathy (66) and early neuropathy (65).
Cardiovascular disease is responsible for up to 65% of all 
deaths in diabetic patients (67). Probiotic supplementation can 
help improve the lipid profile of patients with T2DM. The same 
group from the study mentioned above showed that consuming 
probiotic yogurt enriched with L. acidophilus (La5) and B. lactis 
(Bb12) resulted in a 4.54% decrease in total cholesterol and a 
7.45% decrease in LDL-C compared with patients who consumed 
regular, unenriched yogurt (58). There was no significant change 
in triglyceride or high-density lipoprotein cholesterol levels. 
Using the same probiotics, a different group of researchers found 
that supplementation with L. acidophilus (La5) and B. lactis 
(Bb12) caused a significant increase in HDL-C and a decrease in 
the ratio of LDL-C:HDL-C (68). Although these effects are mild 
compared with statins, the greatest predictor of cardiovascular 
events in diabetes is the loss of HRV combined with numb feet 
(6, 69). The effects of these probiotics on the ANS remain to be 
shown.
Fecal Microbiota Transplant
Changes in the gut microbiota contribute to energy homeostasis 
and, therefore, the pathophysiological progression to diabetes 
and obesity. Studies have shown that alterations that occur within 
the gut flora allow obese animals to harvest a greater portion of 
energy from their diet (7). It has also been demonstrated that 
mice with sterile intestines that were fed a high-fat “western diet” 
did not develop obesity, insulin resistance, or dyslipidemia (70). 
Animal studies have shown that fecal microbiota transplant from 
a genetically bred obese mouse to a genetically bred lean mouse 
can transform the recipient to be the habitus of the donor (71).
Conceptually, a potential rebalancing of the gut flora in obese, 
diabetic patients could positively influence their energy homeo-
stasis. A recent double-blinded, RCT studied the therapeutic 
effects of allogeneic lean donor feces infusion on insulin resist-
ance in male patients with the metabolic syndrome (or, in the case 
of the control group, an autologous transplant) (72). Six weeks 
later, they found that the patients who had received an allogeneic 
transplant from lean donors had improved insulin sensitivity 
(median rate of glucose disappearance increased from 26.2 to 
45.3 μmol/kg/min). They also found an increased abundance of 
butyrate-producing gut microbiota, which they concluded could 
be the reason for the improved insulin sensitivity, given the role 
of butyrate in increasing energy expenditure and mitochondrial 
function. Of note, butyrate stimulates the release of GLP-1 and 
enhances the beneficial effects of vagal activation. These favorable 
alterations in glucose metabolism support the notion that recon-
stituting commensal microflora with lean microflora might be 
a novel therapeutic intervention by reestablishing a “healthier” 
host environment.
THe CHOLiNeRGiC ANTi-
iNFLAMMATORY PATHwAY iN DiABeTeS 
AND OBeSiTY
The inflammatory response is controlled by neural circuitry of 
the autonomic nervous system. The afferent arc consists of nerves 
that sense the injury and infection, and this in turn activates a 
cholinergic anti-inflammatory pathway that modulates the 
response and is the potential target for future therapies of dia-
betes (73, 74). The lymphoid organs of the immune system are 
innervated by cholinergic, catecholaminergic, dopaminergic, and 
peptidergic neurons, and the neurotransmitters can interact with 
immune cells and alter their level of function. For instance, in the 
non-obese diabetic (NOD) mouse (an animal model for type 1 
diabetes), neurons surrounding the pancreatic beta cells are lost 
before there is damage to the islet, and the loss of tonic inhibitory 
signals contributes to the subsequent beta cell destruction (75). 
In addition, destruction of the capsaicin-sensitive nerve fibers of 
the pancreas protect the beta cell from streptozotocin-induced 
beta cell injury (capsaicin and STZ) (76). Thus, it seems that to 
begin to understand the role of the autonomic nervous system in 
its more complex role in inflammation and autoimmunity, one 
needs to delve further into this complexity. Like St. Thomas, we 
need to probe deeper!
Watkins and colleagues discovered that sensory neurons detect 
the presence of inflammation in tissues (77). These responses to 
IL-1-induced inflammation were mediated by the vagus nerve 
and could be abolished by vagotomy or a selective competitive 
antagonist of the IL-1 receptor (78, 79).
There are a number of ligands other than IL-1 derived from 
macrophages, monocytes, and dendritic cells referred to as 
pathogen-associated molecular patterns (PAMPs), which activate 
TLRs, leading to increased expression of NF-κB and increased 
release of inflammatory cytokines such as TNFα and IL-6. 
Endogenous molecular products are also released from damaged 
cells and are referred to as damage-associated molecular patterns 
(DAMPs). Thus, the nervous system is capable of initiating a 
response to tissue injury and inflammation and can per se initiate 
a pro-inflammatory response.
The neurotransmitter of the efferent arc acetylcholine interacts 
with the innate immune cells that express the nicotinic acetyl-
choline receptor subunit α7 (α7nAChR). The receptor is widely 
expressed in neurons that function as ligand-gated ion channels 
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encoded by CHRNA 7 on chromosome 15q14 and is a product 
of 10 exons yielding a mature protein of 50 kDa. α7nAChR has 
a tonic inhibitory role in the immune cells similar to the effects 
of the parasympathetic system on inhibition of heart rate. 
Exaggerated responses to inflammatory molecules are caused by 
vagotomy, whereas stimulation of the vagus downregulates the 
production of TNFα, IL-1, IL-6, and IL-8 but does not alter the 
anti-inflammatory cytokine IL-10 and TGFβ. This ACh activates 
the JAK/STAT pathway, affecting the inflammatory responses 
mediated by NF-κB and initiating the release of a variety of 
inflammatory cytokines. Thus, this is a defensive reflex protecting 
the organism from organ damage and death when exposed to 
syndromes of excess cytokine release such as infection, trauma, 
and stress.
We have hypothesized that in the metabolic syndrome and 
diabetes, there is a constant increase in low-grade inflammation 
mediated by a large cadre of exogenous and endogenous ligands 
(Figure 1). These, in turn, are capable of binding to the advanced 
glycation end product receptor (RAGE), thereby activating 
NF-κB pathway and increasing the production of inflammatory 
cytokines. In addition, there are a number of other ligands capable 
of activating the inflammatory cascade. DAMPs, for example, can 
stimulate innate immune responses culminating in NF-κB activa-
tion as with the ligands for RAGE. This is further compounded by 
the ligands binding to the TLRs, which potentiate the activation 
of NF-κB. The balance occurs by binding of acetylcholine to the 
α7nACHR receptor restraining the activation of NF-κB-mediated 
inflammation. Thus, the loss of autonomic control with reduction 
of parasympathetic activity, hallmark autonomic dysfunction in 
diabetes, initiates a cascade of inflammatory responses that if 
continued unabated will culminate in considerable morbidity and 
mortality. The possible approaches to enhancing parasympathetic 
function will be discussed below.
We (60) examined patients with newly diagnosed diabetes, 
established diabetes and healthy controls and analyzed a cadre 
of inflammatory markers in addition to time and frequency 
domain measures of autonomic function. Of great interest to us 
is the appearance before the advent of inflammation of loss of 
sympathetic/parasympathetic (S/P) balance. Early in the devel-
opment of autonomic dysfunction, there is loss of S/P balance, 
and this correlates with an increase in circulating markers of 
inflammation, such as CRP and IL-6, and a reduction of the high 
molecular weight adiponectin/leptin ratios, which correlate with 
loss of parasympathetic function reflected by changes in the LF/a/
HFa frequency ratios and a reduction in the RMSSD and SDNN 
in time and frequency evaluation of cardiac autonomic func-
tion (66, 80, 81). Activation of the efferent arm of the reflex arc 
(through the administration of an acetylcholine receptor agonist) 
causes a decrease in pro-inflammatory cytokine production and a 
reduction in disease severity (82, 83). In his review, Tracey points 
out a number of important clinical studies that show correlations 
between vagal nerve activity and inflammatory human diseases, 
such as rheumatoid arthritis and lupus (74). They considered 
that inhibition of macrophage function is mediated by Ach 
released by the vagus acting on specific alpha7nicotinic receptors 
expressed by the immune cell. Our results are in keeping with 
this research and suggest that such a reflex arc may be involved 
in the inflammation seen early in T2D. However, our studies 
implicate the hypothalamus as the conductor of the endocrine 
orchestra and show that the earliest changes that are detectable in 
the evolution of diabetes are abnormalities in autonomic balance. 
It is not beyond the realms of reason that we could reverse the 
unfortunate evolutionary profile by targeting the hypothalamic 
set point of autonomic balance, thereby restoring the efferent arm 
of the cholinergic anti-inflammatory pathway.
The relationship between binding of ligands to the pattern 
recognition AGE receptor (RAGE) and inflammation, gene 
expression, oxidative and nitrosative stress, and damage to the 
macro- and microvasculature is not entirely clear. Elevated 
levels of glucose bind to proteins and form AGEs, which bind to 
RAGEs. RAGE signaling activates NADPH oxidase and produc-
tion of reactive oxygen species (ROS). Increased ROS increases 
advanced oxidation protein products (AOPPs), more AGEs, and 
AGE-modification of oxidized LDLs (oxLDLs). Furthermore, 
increased ROS may deplete glutathione, thereby suppressing 
glyoxalase I activity, a mechanism favoring further AGE accu-
mulation. AGEs, AOPPs, macrophage glycoprotein (MAC-1), 
and AGE-oxLDL ligands of RAGE sustain stimulation of RAGE, 
and these processes, together with increased ROS, activate key 
transcription factors, such as nuclear factor-κB (NF-κB) and 
Egr-1, which increase gene transcription factors and activate 
inflammatory mechanisms. Consequences include increased 
migration and activation of RAGE-expressing neutrophils, 
monocytes/macrophages, T-cells, and dendritic cells. This results 
in the release of the pro-inflammatory RAGE ligands S100/cal-
granulins and high-mobility group protein box-1 (HMGB1). In 
this inflammatory environment, further AGEs may be formed as 
well. Via interaction with RAGE, these ligands magnify activation 
of NF-κB, Agr-1, and other factors, thereby amplifying cellular 
stress and tissue damage leading to neurovascular dysfunction. 
Soluble RAGE (sRAGE) is formed from the cleavage of RAGE by 
disintegrins, such as ADAM 10, a metalloproteinase, and β- and 
γ-secretases. sRAGE or a spliced variant (esRAGE) compete for 
binding of ligands to RAGE, and a deficiency could theoretically 
initiate the sequence of events activating an inflammatory cascade 
with an increase in the expression of pro-inflammatory cytokines 
[E-selectin, endothelin-1 tissue factor, vascular endothelial 
growth factor, and other pro-inflammatory cytokines (interleu-
kin-6 and tumor necrosis factor-α)] and damage to neurons, 
kidney, eye, the vasculature, and even bone. Increasing sRAGE 
or its administration could competitively reduce activation of the 
AGE/RAGE pathway and it consequences (5).
Vagal chemoreceptors could be activated directly by substances, 
such as short-chain fatty acids that can be transported across the 
epithelial barrier to the portal circulation (84), or by paracrine 
mediators, such as 5-HT, histamine, CCK, ATP, or glucagon-like 
peptides released by the various mucosal epithelial layer taste 
cells (85, 86). That vagal mucosal chemoreceptors might be 
involved in activation of the “microbiome–gut–brain axis” (85), 
which is substantiated by animal studies where beneficial bacteria 
were applied to the epithelium at known concentrations and vagal 
nerve activity was recorded. There is now strong evidence from 
animal studies that gut microorganisms can activate the vagus 
nerve and that such activation plays a critical role in mediating 
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effects on the brain and, subsequently, behavior. The anxiogenic 
effect of orally administered subclinical doses of Campylobacter 
jejuni on mice was associated with a significant increase in 
c-Fos expression in neurons bilaterally in the vagal ganglia and 
activated visceral sensory nuclei in the brainstem. The areas of 
brainstem activation, the NTS and lateral parabrachial nucleus, 
participate in neural information processing that ultimately lead 
to autonomic neuroendocrine and behavioral responses (87). 
These findings suggest that the influence of the bacteria on auto-
nomic neurotransmission is mediated centrally, likely through 
histaminergic nerves and the suprachiasmatic nucleus (88). 
In a pioneering study, intraduodenal injection of a Lactobacillus 
johnsonii strain increased gastric vagus massed multiunit fir-
ing within 15 min of application (88). Given what is known of 
the vagal anti-inflammatory reflex, it seems plausible that gut 
microbiota-induced modulation of vagal mediated “periphery to 
brain” signaling could translate into changes in efferent neural 
pathways controlling immune responses (89).
CONCLUSiON
Currently, the depth and breath of the gut microbiome and its 
implications on obesity, the pathogenesis of diabetes, and its role 
in the autonomic cholinergic anti-inflammatory pathway that 
influences health and disease remain poorly understood. The 
microbiota gut–brain axis is a complex, bidirectional communica-
tion, which we are currently in the initial stages of understanding. 
It appears as though there are strong implications that intestinal 
dysbiosis via regulation of SCFAs, other paracrine mediators, 
the critical role of the gut microbiota in endotoxemia, and the 
effects of LPS on neurons are associated with obesity, metabolic 
syndrome, and diabetes and its complications.
Associated with the intestinal dysbiosis, animal studies have 
demonstrated an associated chronic low-grade inflammatory 
state, which is likely to play a contributing, if not a pivotal, role 
in diabetic-associated disorders. Clearly, the onset of diabetes is 
heralded by impairment of HRV, dictated by disordered hypo-
thalamic function, which may owe its origin to the gut dysbiosis.
These seminal data offer significant translational opportuni-
ties for further research. Clinical studies evaluating the thera-
peutic and preventive strategies to prevent or alter this dysbiosis 
are clearly needed and offer potential new pathways for disease 
management.
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